Rachakatla Raja Shekar, Pyle Marla M, Ayuzawa Rie, Edwards Sarah M, Marini Frank C, Weiss Mark L, Tamura Masaaki, Troyer Deryl
Department of Anatomy & Physiology, Kansas State University, Manhattan, Kansas 66506, USA.
Cancer Invest. 2008 Aug;26(7):662-70. doi: 10.1080/07357900701871134.
Umbilical cord matrix stem (UCMS) cells that were engineered to express interferon-beta (IFN-beta) were transplanted weekly for three weeks into MDA 231 breast cancer xenografts bearing SCID mice in combination with 5-fluorouracil (5-FU). The UCMS cells were found within lung tumors but not in other tissues. Although both treatments significantly reduced MDA 231 tumor area in the SCID mouse lungs, the combined treatment resulted in a greater reduction in tumor area than by either treatment used alone. These results indicate that a combination treatment of UCMS-IFN-beta cells and 5-FU is a potentially effective therapeutic procedure for breast cancer.
经过基因工程改造以表达β干扰素（IFN-β）的脐带基质干细胞（UCMS细胞），每周移植一次，连续三周，与5-氟尿嘧啶（5-FU）联合，移植到患有MDA 231乳腺癌异种移植瘤的SCID小鼠体内。在肺肿瘤中发现了UCMS细胞，但在其他组织中未发现。尽管两种治疗方法都显著减小了SCID小鼠肺部MDA 231肿瘤的面积，但联合治疗导致的肿瘤面积减小幅度比单独使用任何一种治疗方法都更大。这些结果表明，UCMS-IFN-β细胞与5-FU的联合治疗是一种潜在有效的乳腺癌治疗方法。
